CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $191.13M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.63×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
191.13MUSDvs all stocks (USD)
Revenue (TTM)
17.56MUSDvs all stocks (USD)
Beta
1.68xvs all stocks
52-Week Change
-62.95%vs all stocks
Market Capitalization
191.13MUSDvs all stocks (USD)
Enterprise Value
1.21MUSDvs all stocks (USD)
Forward P/E
-1.54xvs Biotechnology peers
Price to Sales (TTM)
10.91xvs Biotechnology peers
Price to Book (MRQ)
0.6265xvs Biotechnology peers
Enterprise to Revenue
0.0690xvs Biotechnology peers
Enterprise to EBITDA
-0.0080xvs Biotechnology peers
Gross Margin
77.06%vs Biotechnology peers
Operating Margin
-603.91%vs Biotechnology peers
Return on Assets (TTM)
-41.92%vs Biotechnology peers
Return on Equity (TTM)
-72.33%vs Biotechnology peers
Revenue (TTM)
17.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.68USDUpdated Jul 9, 2026Quarterly Revenue Growth
183.20%vs Biotechnology peers
Gross Profit (TTM)
10.28MUSDvs all stocks (USD)
EBITDA (TTM)
-149.20MUSDvs all stocks (USD)
Net Income (TTM)
-147.39MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
183.16%vs Biotechnology peers
Operating Cash Flow (TTM)
-125.58MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-76.73MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
13.11MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.64MUSDFY2025 · Dec 31, 2025Gross Profit
6.47MUSDFY2025 · Dec 31, 2025Operating Income
-122.69MUSDvs all stocks (USD)
Pre-tax Income
-124.02MUSDFY2025 · Dec 31, 2025Net Income
-124.02MUSDFY2025 · Dec 31, 2025EBIT
-123.93MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-119.92MUSDFY2025 · Dec 31, 2025Research & Development
44.49MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
87.68MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-3.01MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
89.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-14.57USDFY2025 · Dec 31, 2025EPS (Diluted)
-14.57USDFY2025 · Dec 31, 2025Basic Shares Outstanding
8.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
8.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-124.02MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-109.38MUSDFY2025 · Dec 31, 2025Free Cash Flow
-112.75MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
209.81MUSDFY2025 · Dec 31, 2025Interest Paid
89.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-124.02MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.93MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.02MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.90MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-2.62MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.99MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.42MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.37MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.16MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-4.53MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-9.65MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-13.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
214.53MUSDFY2025 · Dec 31, 2025Shares Outstanding
14.21MSharesUpdated Jul 9, 2026Shares Short
2.87MSharesUpdated Jul 9, 2026Short Ratio
6.37daysvs all stocks
Short % of Shares Outstanding
18.01%vs all stocks
% Held by Insiders
0.13%vs all stocks
% Held by Institutions
45.63%vs all stocks
Total Cash (MRQ)
185.47MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.63USDUpdated Jul 9, 2026Total Debt (MRQ)
1.29MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0057xvs Biotechnology peers
Current Ratio (MRQ)
6.99xvs Biotechnology peers
Book Value per Share (MRQ)
19.17USDUpdated Jul 9, 2026Total Assets
277.17MUSDvs all stocks (USD)
Total Current Assets
228.88MUSDFY2025 · Dec 31, 2025Total Liabilities
32.02MUSDFY2025 · Dec 31, 2025Total Non-current Assets
48.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.18MUSDFY2025 · Dec 31, 2025Total Current Liabilities
30.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
207.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.27MUSDFY2025 · Dec 31, 2025Inventory
7.01MUSDFY2025 · Dec 31, 2025Accounts Payable
8.11MUSDFY2025 · Dec 31, 2025Short-term Debt
125.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
3.42MUSDFY2025 · Dec 31, 2025Other Current Liabilities
5.12MUSDFY2025 · Dec 31, 2025Long-term Debt
1.18MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-854.72MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
245.15MUSDvs all stocks (USD)
52-Week Low
10.03USDUpdated Jul 9, 202652-Week High
69.97USDUpdated Jul 9, 202652-Week Change
-62.95%vs all stocks
Beta
1.68xvs all stocks
50-Day MA
12.94USDUpdated Jul 9, 2026200-Day MA
16.88USDUpdated Jul 9, 2026Avg 10-Day Volume
538.94KSharesUpdated Jul 9, 2026Avg 30-Day Volume
468.97KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-14.66USDUpdated Jul 9, 2026Other Income / Expense
-5.39MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.63×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.63Industry median: 2.97Industry P5: 1.03Peers compared: 261
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.99Altman Z-Score: -1.31
Financial Health
Altman Z-Score -1.31: distress zoneCritical
Altman Z-Score: -1.31
Low earnings qualitySignificant
Earnings Quality Score: -0.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $191.13M, lower than 95% of all stocks globallySignificant
Market cap (USD): 191,130,203Global P5: 269,387,740.27
Revenue is $17.56M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,556,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Eos Energy Enterprises Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC